Back to search results

The BOOST Trial: Exercise Training for Lung Cancer Immunotherapy

This study, called the BOOST Trial, is looking at how exercise training might improve immune activity and help patients with non-small cell lung cancer (NSCLC) respond better to immunotherapy. Immunotherapy uses your body's own immune system to fight cancer, but it doesn't work for everyone. Researchers believe exercise can boost your immune system. If you join, you'll either participate in virtual home-based aerobic interval training using a stationary bike, or receive a healthy lifestyle guidebook. The study will measure changes in your neutrophil-to-lymphocyte ratio (NLR), which is a marker of immune activity, at the beginning and after 26 weeks. This study is currently recruiting 100 participants who are at least 18 years old, have NSCLC, and are already receiving immunotherapy.

Study design
This is an interventional study with 100 planned participants. You would be randomly assigned to one of two groups.
What's involved
You would complete virtual home-based aerobic interval training sessions, or receive a healthy lifestyle guidebook. You would also undergo blood tests, DEXA scans (to measure bone density), lung function tests, physical fitness tests, and fill out questionnaires throughout the study.
Compensation
Not stated in the trial record.
Follow-up
After the main study intervention, you would be followed up at week 26 and then every 3 months until your immunotherapy treatment is complete.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06983899

Exercise Training for the Improvement of Immune Activity and Treatment Outcomes During Immunotherapy for Non-small Cell Lung Cancer, BOOST Trial

Recruiting
NAAges 18+InterventionalSupportive care
Fred Hutchinson Cancer Center
~100 participants
Updated 2026-06-23 on ClinicalTrials.gov
What's tested:Aerobic ExerciseExercise InterventionEducational InterventionDual X-ray AbsorptiometryElectronic Health Record ReviewCardiopulmonary Exercise Testing

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Mean difference in neutrophil-to-lymphocyte ratio (NLR)
Measured over Baseline (Week 1) and post-intervention (Week 26)

Conditions

Lung Non-Small Cell Carcinoma

Explore related trials

Lung Non-Small Cell Carcinoma

Where it's being run

1 sites across 1 states
Washington1

Study leadership

  • Dong-Woo Kang, PhD · PRINCIPAL_INVESTIGATOR · Fred Hutch/University of Washington Cancer Consortium

Who to contact

Dong-Woo Kang, PhD
[email protected]
206-667-5188
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥ 18 years.
Histologically diagnosed with NSCLC.
Currently receiving immunotherapy with a minimum of one month of treatment completed.
Having a plan to continue immunotherapy for at least 24 weeks (i.e., study intervention period) at the time of recruitment.
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2, indicating the ability to fulfill physical fitness and function assessments.
Able to understand and willingness to provide study consent.

Exclusion

Participating in ≥ 150 minutes of moderate-to-vigorous aerobic exercise per week over the past month. This study targets insufficiently active persons to assess the effect of the described exercise intervention, where additional exercise done regularly will contaminate the intervention outcomes.
Having medical conditions clinically unstable or uncontrollable, with medications that are deemed high-risk for exercise participation by the study team in consultation with the treating oncologist, using the electric medical record (EMR) and Physical Activity Readiness Questionnaire (PAR-Q). This includes but is not limited to: recent (\< 6 months) myocardial infarction, uncontrolled arrhythmias, decompensated heart failure, unstable angina, symptomatic severe aortic stenosis, uncontrolled hypertension (≥ 180/110 mmHg), uncontrolled diabetes (hemoglobin A1c \[HbA1c\] \> 10% with symptoms), severe chronic obstructive pulmonary disease requiring hospitalization in past 3 months, and bone metastases with imminent fracture risk. These exclusions are based on the American College of Sports Medicine (ACSM)'s Guidelines for Exercise Testing and Prescription and the American Association of Cardiovascular and Pulmonary Rehabilitation (AACPR)'s Guidelines for Cardiac Rehabilitation Programs for safe exercise in clinical populations.
Having a high risk for noncompliance with study procedures, including but not limited to: informed consent, participation in outcome assessments, completion of fasting blood draws, attendance at scheduled sessions, adherence to supervised virtual exercise sessions, and appropriate use of provided monitoring equipment (e.g., heart rate monitor, blood pressure monitor, SpO2 monitor). This determination will be based on a composite assessment of the following factors: history of missed oncology appointments (i.e., three or more uninformed no-shows in the prior six months) and poor responsiveness to study communications (i.e., three or more repeated unreturned calls or emails during the recruitment stage). We will also consider any demonstrated difficulty following instructions during initial scheduling or onboarding, or clinical concern raised by the referring provider. Participants meeting one or more of these criteria likely to impair participation will be considered ineligible.
Patients who are non-English speaking that would prevent their participation in the participant survey.

What this trial measures

  • Mean difference in neutrophil-to-lymphocyte ratio (NLR)Baseline (Week 1) and post-intervention (Week 26)

    The primary analysis will follow an intention-to-treat approach, using a two-sample t-test to compare changes in NLR from baseline between the groups.